Amorfix receives support from Canadian government to accelerate development of blood test for Alzheimer's disease
Amorfix Life Sciences Ltd. announced that in addition to their own investment, the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) will share in the research and development of the company's proposed diagnostic test for Alzheimer's disease, EP-AD(tm), via a contribution of $322,000.
The NRC-IRAP support will be focused on the extension of Amorfix's patent-pending Epitope Protection (EP) technology platform to the diagnosis of Alzheimer's disease, using a standard blood sample. NRC-IRAP is a federal government program that provides a range of both technical and business oriented advisory services along with potential financial support to growth-oriented Canadian small and medium-sized enterprises.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.